12 High Growth International Stocks to Invest in Now

Page 6 of 11

6. Argenx SE (NASDAQ:ARGX)

10-Year Revenue Growth Rate: 79.79%

Number of Hedge Fund Holders: 43

Founded in 2008, Argenx SE (NASDAQ:ARGX) is a Netherlands-based biopharmaceutical company focused on developing antibody-based therapies for autoimmune diseases and cancer. The company is known for its Vyvgart flagship drug, recognized as the first approved neonatal Fc receptor (FcRn) blocker in the United States, European Union, Japan, and other regions for treating generalized myasthenia gravis (gMG).

Vyvgart got approved in 2021 and has since then significantly exceeded expectations. Analysts expect that it could generate over $5 billion in peak sales, driven by a substantial unmet need in this therapeutic area. During the fiscal third quarter of 2024, Argenx SE (NASDAQ:ARGX) grew its revenue by 74% year-over-year to reach $589 million. Out of this total revenue, Vyvart contributed $573 million from net global sales.

Argenx SE (NASDAQ:ARGX) is advancing several other candidates through its antibody discovery platform, including empasiprubart, which targets rare neurological diseases like multifocal motor neuropathy (MMN). Moreover, management has signed a partnership with Zai Lab to market Vyvgart in China, which adds potential for long-term sales growth. It is one of the high-growth international stocks to invest in now.

Page 6 of 11